Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial by de Bono, Johann S, Prof, Mehra, Niven, PhD, Scagliotti, Giorgio V, Prof, Castro, Elena, PhD, Dorff, Tanya, MD, Stirling, Adam, MD, Stenzl, Arnulf, Prof, Fleming, Mark T, MD, Higano, Celestia S, MD, Saad, Fred, MD, Buttigliero, Consuelo, PhD, van Oort, Inge M, PhD, Laird, A Douglas, PhD, Mata, Marielena, PhD, Chen, Hsiang-Chun, PhD, Healy, Cynthia G, BS, Czibere, Akos, MD, Fizazi, Karim, Prof

Get full text

Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer by Westdorp, Harm, MD, Kuip, Evelien J.M., MD, van Oort, Inge M., MD, PhD, Kramers, Cornelis, MD, PhD, Gerritsen, Winald R., MD, PhD, Vissers, Kris C.P., MD, PhD, FIPP

Get full text

Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review by Surcel, Cristian I., M.D., Ph.D, van Oort, Inge M., M.D., Ph.D, Sooriakumaran, Prasanna, M.D., Ph.D, Briganti, Alberto, M.D., Ph.D, De Visschere, Peter J.L., M.D, Fütterer, Jurgen J., M.D, Ghadjar, Pirus, M.D., Ph.D, Isbarn, Hendrik, M.D., Ph.D, Ost, Piet, M.D., Ph.D, van den Bergh, Roderick C.N., M.D., Ph.D, Yossepowitch, Ofer, M.D., Ph.D, Giannarini, Gianluca, M.D, Ploussard, Guillaume, MD, PhD

Get full text